Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sharper tumor maps: PET scans could tighten radiation beams

NCT ID NCT00809016

Diagnosis Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are studying whether PET scans help doctors plan radiation more precisely for people with locally advanced head and neck cancer. Participants receive 3-dimensional conformal radiation therapy and intensity-modulated radiation therapy, which shape beams to the tumor. The trial compares the tumor volume identified by standard imaging with the volume identified by PET, to see if PET changes where radiation is aimed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PET imaging with fludeoxyglucose F 18, plus 3-dimensional conformal and intensity-modulated radiation therapy
What this could lead to
If PET scans map head and neck tumors more precisely than standard imaging, doctors could aim radiation more tightly and spare healthy tissue.
What could go wrong
This small study tests a planning method, not a cure, and it may not show a meaningful difference. PET scans can also flag harmless inflammation as suspicious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Start date

May 2007

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

DISEASE CHARACTERISTICS: * Histologically confirmed head and neck cancer * No nasopharyngeal or paranasal sinus cancer * Locally advanced disease (T3 or T4) * Not in complete remission * Planning to undergo curative radiotherapy (minimum dose of 66 Gy), with or without standard treatment (i.e., platinum-based chemotherapy or biological therapy/rituximab) * Measurable tumor according to RECIST criteria PATIENT CHARACTERISTICS: * WHO performance status 0-2 * Not pregnant or nursing * Able to lie still for 1 hour * No history of progressive neoplastic disease * No known hypersensitivity to fludeoxyglucose F18 or any of its excipients * No severe or uncontrolled systemic disease, including any of the following: * Kidney disease * Liver disease * Cardiac disease * Unstable or uncompensated respiration * Uncontrolled diabetes (i.e., glucose ≥ 1.5 g/L) * No geographical, social, or psychological conditions that make follow-up impossible PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior surgery * No concurrent experimental agents

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms salivary gland cancer Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancer

Contacts and locations

Locations

  • Centre Oscar Lambret

    Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.